Welcome to our dedicated page for ARCELLX news (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on ARCELLX stock.
Arcellx, Inc. (NASDAQ: ACLX) is a clinical-stage biotechnology company focused on cell therapy and immunotherapies for cancer and other incurable diseases. Its news flow is heavily driven by clinical data updates, regulatory interactions, and collaboration milestones related to its lead BCMA-directed CAR T-cell therapy, anitocabtagene autoleucel (anito-cel), for relapsed or refractory multiple myeloma.
Investors and observers following Arcellx news can expect regular announcements on the company’s pivotal Phase 2 iMMagine-1 study and its global Phase 3 iMMagine-3 trial. Recent releases have highlighted high overall response rates, deep responses, and high minimal residual disease (MRD) negativity in heavily pretreated multiple myeloma patients, along with detailed safety observations such as the absence of specific delayed neurotoxicities in reported data cuts.
Arcellx also issues news on key regulatory milestones, including a pre-BLA meeting with the U.S. Food and Drug Administration for anito-cel and the addition of MRD negativity as a dual primary endpoint in iMMagine-3. Updates on FDA designations for anito-cel, such as Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy status, are part of this regulatory-focused news stream.
Beyond multiple myeloma, Arcellx news covers pipeline expansion, such as FDA clearance of an IND for ACLX-004 targeting CD33 and CD123 using the ARC-SparX platform, as well as financial results, cash runway commentary, and collaboration developments with Kite, a Gilead Company. Coverage also includes participation in major scientific meetings like EHA and ASH, where Arcellx presents clinical data and scientific findings. For readers tracking ACLX, this news page provides a centralized view of clinical, regulatory, financial, and corporate developments that shape the company’s progress in cell therapy.
Arcellx, Inc. (NASDAQ: ACLX) has appointed Maryam Abdul-Kareem, J.D., as General Counsel, bringing extensive experience in the biopharmaceutical industry from her previous roles at Kinnate Biopharma and AstraZeneca. Abdul-Kareem's responsibilities will include overseeing legal, contracts, and compliance matters as the company scales its operations. CEO Rami Elghandour emphasized her leadership skills and commitment to diversity as vital for the company’s growth.
Arcellx is focused on developing innovative immunotherapies for cancer and related diseases, including its lead candidate CART-ddBCMA.
Arcellx, Inc. (NASDAQ: ACLX) has successfully closed its upsized public offering, raising $128.8 million through the sale of 8,050,000 shares of common stock at $16.00 per share. This includes the full exercise of an option by underwriters to purchase an additional 1,050,000 shares. The offering, which was registered with the SEC and became effective on June 15, 2022, aims to advance Arcellx's innovative immunotherapies, including CART-ddBCMA for multiple myeloma and ARC-SparX for various cancers.
Arcellx, Inc. (NASDAQ: ACLX) announced a follow-on public offering of 7,000,000 shares at $16.00 per share, raising $112 million in gross proceeds. This offering is an increase from the initial size of 4,000,000 shares. Underwriters have a 30-day option to purchase an additional 1,050,000 shares. The offering is set to close on June 21, 2022. BofA Securities, SVB Securities, William Blair, and Canaccord Genuity are acting as joint book-running managers.
Arcellx, Inc. (NASDAQ: ACLX) presented promising Phase 1 results for its CART-ddBCMA therapy targeting relapsed or refractory multiple myeloma. Among 31 evaluable patients, a 100% overall response rate was observed, with 71% achieving complete (CR) or stringent complete (sCR) responses. Notably, long-term data showed that 81% of patients dosed over 12 months reached CR/sCR. The treatment was well-tolerated, with no severe toxicities reported. A pivotal Phase 2 study is expected to initiate by the end of 2022. These findings highlight the therapy's potential as a leading treatment option.
Arcellx, Inc. (NASDAQ: ACLX) has appointed Michelle Gilson as the new Chief Financial Officer. Gilson previously served as a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, specializing in biotechnology. Her extensive background in capital markets will enhance Arcellx's financial strategy as they advance their innovative cell therapies aimed at treating cancer. The lead product candidate, CART-ddBCMA, is in an ongoing Phase 1 study and has received multiple FDA designations, underscoring the company's commitment to developing effective treatment options.
Arcellx, Inc. (NASDAQ: ACLX) announced the appointment of Olivia Ware to its Board of Directors, replacing Lewis T. "Rusty" Williams, M.D. Ware brings over 20 years of experience in biotech and pharmaceutical drug development, having played key roles in launching major oncology drugs such as Rituxan and Herceptin. Her expertise is expected to enhance the company's strategic direction, especially as it prepares for a Phase 2 study of CART-ddBCMA for relapsed or refractory multiple myeloma. The company is focused on advancing innovative immunotherapies and has received multiple FDA designations for its lead product.
Arcellx, Inc. (NASDAQ: ACLX) initiated a Phase 1 clinical trial for ACLX-001 utilizing its innovative ARC-SparX technology to treat relapsed or refractory multiple myeloma (r/r MM). The company raised $142 million in its IPO and reported cash reserves of $210.9 million as of March 31, 2022, sufficient to fund operations into late 2023. Unfortunately, they posted a net loss of $32.4 million with R&D expenses increasing to $24.4 million. Upcoming presentations at the ASCO Annual Meeting are anticipated to provide further insights into their clinical data.
Arcellx, Inc. (NASDAQ: ACLX) has initiated its Phase 1 clinical trial for ACLX-001, targeting relapsed or refractory multiple myeloma (r/r MM). The trial, utilizing the innovative ARC-SparX platform, aims to evaluate safety and tolerability while addressing challenges like dose-limiting toxicities and tumor heterogeneity. The first patient has been dosed, and initial data is expected in 2023. The ARC-SparX technology combines SparX proteins and ARC-T cells to enable controlled and adaptable treatment options, potentially enhancing patient access to CAR-T therapies.
On May 9, 2022, Arcellx, Inc. (ACLX) announced key clinical data for CART-ddBCMA from its ongoing Phase 1 study aimed at treating relapsed or refractory multiple myeloma. Published in Blood Advances, the findings show a 100% overall response rate (ORR) and a 75% complete response/sustained complete response (CR/sCR) in 12 patients. The trial reported no significant adverse effects, solidifying CART-ddBCMA's safety profile. Following these results, Arcellx plans to expand the study and present new data at ASCO on June 5, with a pivotal Phase 2 study expected later in 2022.
Arcellx, Inc. (NASDAQ: ACLX) will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:00 p.m. E.T. The discussion will be accessible via a live webcast on the company's website and will be archived for 30 days. Arcellx focuses on developing advanced immunotherapies for cancer and other diseases, with its lead candidate CART-ddBCMA currently in a Phase 1 study for relapsed or refractory multiple myeloma. The company holds multiple designations from the FDA to expedite its clinical development.